Език: EN EN
← Назад към резултатите
Само по покана NCT05039866

Long-Term Follow-up of Subjects Who Were Treated With ST-920

Заболявания: Fabry Disease Fabry Disease, Cardiac Variant

Спонсор: Sangamo Therapeutics

Налично на: БГ
Обобщение
Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.
Описание
Non-interventional, multi-center, long-term follow-up (LTFU) study of subjects dosed with ST-920 in the clinical study ST-920-201. All subjects dosed in the study who completed at least 52 weeks post-infusion follow-up in their primary protocol will be offered to participate. Subjects who enroll will be monitored for a total of up to 5 years following ST-920 infusion.
Кой може да участва
Inclusion Criteria: * Subjects who received ST-920 therapy in a separate parent trial * Subjects who have consented to participate in this LTFU study. Exclusion Criteria: -This study has no exclusion criteria
Места на провеждане 5
Австралия (1)
The Royal Melbourne Hospital
Parkville , Victoria
Канада (1)
M.A.G.I.C. Clinic Ltd.
Calgary , Alberta
Германия (1)
University Hospital of Würzburg
Würzburg
Великобритания (1)
Addenbrooke's Hospital
Cambridge
САЩ (1)
University of California, Irvine
Irvine , California
Технически детайли
Статус
Само по покана
Вид изследване
OBSERVATIONAL
Пол
Мъже и жени
Минимална възраст
18 Years
Здрави доброволци
Не
Начална дата
16.08.2021
Крайна дата
01.03.2039
Регистрационен номер
NCT05039866
Източник
anzctr
Запитване за медицински туризъм

Информацията е извлечена автоматично от ClinicalTrials.gov. Консултирайте се с вашия лекар преди да предприемете действия.